97 related articles for article (PubMed ID: 11021356)
1. Genotype analysis of the CYP2C19 gene in HCV-seropositive patients with cirrhosis and hepatocellular carcinoma.
Chau TK; Marakami S; Kawai B; Nasu K; Kubota T; Ohnishi A
Life Sci; 2000 Aug; 67(14):1719-24. PubMed ID: 11021356
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms of cytochrome P450 in patients with hepatitis C virus-associated hepatocellular carcinoma.
Mochizuki J; Murakami S; Sanjo A; Takagi I; Akizuki S; Ohnishi A
J Gastroenterol Hepatol; 2005 Aug; 20(8):1191-7. PubMed ID: 16048566
[TBL] [Abstract][Full Text] [Related]
3. CYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancer.
Silvestri L; Sonzogni L; De Silvestri A; Gritti C; Foti L; Zavaglia C; Leveri M; Cividini A; Mondelli MU; Civardi E; Silini EM
Int J Cancer; 2003 Apr; 104(3):310-7. PubMed ID: 12569554
[TBL] [Abstract][Full Text] [Related]
4. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population.
He N; Yan FX; Huang SL; Wang W; Xiao ZS; Liu ZQ; Zhou HH
Eur J Clin Pharmacol; 2002 Apr; 58(1):15-8. PubMed ID: 11956668
[TBL] [Abstract][Full Text] [Related]
5. A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype.
Brøsen K; de Morais SM; Meyer UA; Goldstein JA
Pharmacogenetics; 1995 Oct; 5(5):312-7. PubMed ID: 8563772
[TBL] [Abstract][Full Text] [Related]
6. In vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver disease.
Ohnishi A; Murakami S; Akizuki S; Mochizuki J; Echizen H; Takagi I
J Clin Pharmacol; 2005 Nov; 45(11):1221-9. PubMed ID: 16239354
[TBL] [Abstract][Full Text] [Related]
7. Genotype analysis of the CYP2C19 gene in the Japanese population.
Tsuneoka Y; Fukushima K; Matsuo Y; Ichikawa Y; Watanabe Y
Life Sci; 1996; 59(20):1711-5. PubMed ID: 8890945
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the CYP2C19 polymorphism in a North-eastern Thai population.
Tassaneeyakul W; Tawalee A; Tassaneeyakul W; Kukongviriyapan V; Blaisdell J; Goldstein JA; Gaysornsiri D
Pharmacogenetics; 2002 Apr; 12(3):221-5. PubMed ID: 11927837
[TBL] [Abstract][Full Text] [Related]
9. CYP2A6 gene polymorphism and risk of liver cancer and cirrhosis.
Gullstén H; Agúndez JA; Benítez J; Läärä E; Ladero JM; Díaz-Rubio M; Fernandez-Salguero P; Gonzalez F; Rautio A; Pelkonen O; Raunio H
Pharmacogenetics; 1997 Jun; 7(3):247-50. PubMed ID: 9241665
[No Abstract] [Full Text] [Related]
10. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin.
Ferguson RJ; De Morais SM; Benhamou S; Bouchardy C; Blaisdell J; Ibeanu G; Wilkinson GR; Sarich TC; Wright JM; Dayer P; Goldstein JA
J Pharmacol Exp Ther; 1998 Jan; 284(1):356-61. PubMed ID: 9435198
[TBL] [Abstract][Full Text] [Related]
11. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele.
Xiao ZS; Goldstein JA; Xie HG; Blaisdell J; Wang W; Jiang CH; Yan FX; He N; Huang SL; Xu ZH; Zhou HH
J Pharmacol Exp Ther; 1997 Apr; 281(1):604-9. PubMed ID: 9103550
[TBL] [Abstract][Full Text] [Related]
12. The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients.
Yokono A; Morita S; Someya T; Hirokane G; Okawa M; Shimoda K
J Clin Psychopharmacol; 2001 Dec; 21(6):549-55. PubMed ID: 11763000
[TBL] [Abstract][Full Text] [Related]
13. Correlation between omeprazole hydroxylase and CYP2C19 genotype in North Indians.
Lamba JK; Dhiman RK; Singh R; Kohli KK
Eur J Clin Pharmacol; 2001 Nov; 57(9):649-52. PubMed ID: 11791894
[TBL] [Abstract][Full Text] [Related]
14. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population.
Sviri S; Shpizen S; Leitersdorf E; Levy M; Caraco Y
Clin Pharmacol Ther; 1999 Mar; 65(3):275-82. PubMed ID: 10096259
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus-related hepatocellular carcinoma and liver cirrhosis.
Pecic V; Stankovic-Djordjevic D; Nestorovic M; Radojkovic M; Marjanovic H; Ilic B; Milojkovic M
J BUON; 2011; 16(2):277-81. PubMed ID: 21766498
[TBL] [Abstract][Full Text] [Related]
17. CYP2C19 genetic mutations in North Indians.
Lamba JK; Dhiman RK; Kohli KK
Clin Pharmacol Ther; 2000 Sep; 68(3):328-35. PubMed ID: 11014415
[TBL] [Abstract][Full Text] [Related]
18. Polymerase chain reaction-single-strand conformation polymorphism based determination of two major genetic defects responsible for a phenotypic polymorphism of cytochrome P450 (CYP) 2C19 in the Japanese population.
Itoh K; Inoue K; Nakao H; Yanagiwara S; Tada H; Suzuki T
Anal Biochem; 2000 Aug; 284(1):160-2. PubMed ID: 10933870
[No Abstract] [Full Text] [Related]
19. CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system.
Ford GA; Wood SM; Daly AK
Br J Clin Pharmacol; 2000 Jul; 50(1):77-80. PubMed ID: 10886124
[TBL] [Abstract][Full Text] [Related]
20. A rapid and simple detection of genetic defects responsible for the phenotypic polymorphism of cytochrome P450 2C19.
Itoh K; Inoue K; Yanagiwara S; Kyoya H; Suzuki T
Biol Pharm Bull; 1999 Jan; 22(1):77-9. PubMed ID: 9989666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
